Register for our free email digests:
Revance Therapeutics Inc.
www.revance.com
Latest From Revance Therapeutics Inc.
Mylan Prepares For US Trastuzumab Entry
Mylan is preparing to launch a trastuzumab biosimilar in the US, while progress of developing bevacizumab and aflibercept biosimilars continues. Insulin aspart and glargine are also in Mylan’s pipeline.
Allergan’s Botox Gains Continue, Pipeline Progresses Ahead Of AbbVie Merger
Key Allergan drugs performed well in Q3 and pipeline programs are approaching milestones as AbbVie says its $63bn acquisition of the company remains on track to close early next year.
Mylan Gets Until April 2020 To Decide On Biosimilar Botox Collaboration With Revance
Revance has amended its agreement with Mylan to collaborate on a rival version of Botox to give Mylan more time to decide on whether it wants to continue developing the biosimilar. In turn, Mylan has agreed to pay $5m to Revance for the extended deadline.
Good News For AbbVie: Allergan's Q2 Sales Exceed Expectations, Including Behemoth Botox
AbbVie is buying Allergan for its product sales, both to increase its own revenues and to fund future R&D and business development, so Allergan's Q2 gains are good news.
Company Information
- Industry
-
Biotechnology
- Large Molecule
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Site Specific
- Topical Delivery
-
Drug Delivery
- Therapeutic Areas
- Dermatology
- Gynecological, Urological
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Alias(es)
- Essentia Biosystems Inc.
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Revance Therapeutics Inc.
- Senior Management
-
Mark J Foley, Pres. & CEO
Tobin Schilke, CFO
Abhay Joshi, PhD, COO
Taryn Conway, VP, Mktg. - Contact Info
-
Revance Therapeutics Inc.
Phone: (510) 742-3400
7555 Gateway Blvd.
Newark, CA 94560
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice